Research ArticleArticle
Open Access
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Cristiano B. Campanholo, Ajesh B. Maharaj, Nadia Corp, Stacie Bell, Luisa Costa, Kurt de Vlam, Nicola J. Gullick, Majed Khraishi, Mitsumasa Kishimoto, Natalia Palmou-Fontana, Soumya Reddy, Raffaele Scarpa, Luis Vega, Gleison Vieira Duarte, Devy Zisman, Danielle A. van der Windt, Mehmet T. Duruoz and Alexis Ogdie
The Journal of Rheumatology November 2022, jrheum.220310; DOI: https://doi.org/10.3899/jrheum.220310
Cristiano B. Campanholo
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Ajesh B. Maharaj
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Nadia Corp
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Stacie Bell
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Luisa Costa
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Kurt de Vlam
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Nicola J. Gullick
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Majed Khraishi
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Mitsumasa Kishimoto
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Natalia Palmou-Fontana
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Soumya Reddy
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Raffaele Scarpa
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Luis Vega
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Gleison Vieira Duarte
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Devy Zisman
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Danielle A. van der Windt
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Mehmet T. Duruoz
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Alexis Ogdie
C.B. Campanholo, MD, Santa Casa de São Paulo, São Paulo, Brazil; A.B. Maharaj, PhD, MBBS, Life Westville Hospital, Life Healthcare, Westville, South Africa; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; S. Bell, PhD, National Psoriasis Foundation, Portland, Oregon, USA; L. Costa, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; K. de Vlam, MD, PhD, Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium; N.J. Gullick, PhD, BMBS, Department of Rheumatology, University Hospitals Coventry & Warwickshire, and Warwick Medical School, University of Warwick, UK; M. Khraishi, MD, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada; M. Kishimoto, MD, PhD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; N. Palmou-Fontana, MD, PhD, Rheumatology Deparment, Marqués de Valdecilla University Hospital, Cantabria, Spain; S. Reddy, MD, New York University Grossman School of Medicine, New York City, New York, USA; R. Scarpa, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; L. Vega, MD, Section of Rheumatology, Central Hospital of Peruvian Air Force, Lima, Peru; G.V. Duarte, MD, PhD, Dermatology Division at IBIS, Instituto Bahiano de Imunoterapia, Salvador, Brazil; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; M.T. Duruoz, Rheumatology Division, PMR Department, Marmara University School of Medicine, Istanbul, Turkey; A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. C.B. Campanholo and A.B. Maharaj are co–first authors. ABM is a consultant and received honoraria from Janssen, ThermoFisher, Roche, Novartis, AbbVie, Eli Lilly, AstraZeneca, Pfizer, Zydus. LC received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. NC consulted for and received honoraria from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB; and research funding from AbbVie, AstraZeneca, Izana, Lilly, and Novartis; and conference support from Celgene, Janssen, Lilly, UCB. M. Khraishi is a consultant for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. M. Kishimoto received consulting fees and/ or lecturer's honoraria from AbbVie, Amgen-Astellas, Asahi-Kasei, Astellas, Ayumi, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono, Pfizer, Tanabe-Mitsubishi, Teijin, UCB. SR has consulted for Novartis, Janssen, AbbVie, UCB. GVD received consultancy fees and/or lecturer's honoraria from Novartis, Janssen, AbbVie, Lilly, UCB, Sanofi-Aventis. RS received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Lilly. DZ received consulting fees and/or lecturer's honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer; and grant support from Pfizer, UCB, MSD. MTD received consultancy fees and/or lecturer's honoraria from AbbVie, Amgen, Novartis, Janssen, Lilly. AO has consulted for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa, Lilly, MoonLake, Novartis, Pfizer, UCB; and has received grant support from AbbVie, Amgen, Novartis, Pfizer. CBC, SB, KdeV, NJG, NPF, LV, and DAvdW declare no conflicts relevant to this article. Address correspondence to Dr. A. Ogdie, Perelman School of Medicine, University of Pennsylvania, White 5023, 3400 Spruce St, Philadelphia, PA 19104, USA. Email: ogdiea@pennmedicine.upenn.edu. Accepted for publication August 16, 2022.
Abstract
Objective The 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations provide an evidence-based guide for selecting therapy based on the individual's disease features. Beyond the disease features and associated conditions (eg, uveitis and inflammatory bowel disease), comorbidities play an important role in selecting therapy for an individual patient.
Methods We performed a systematic literature review. We examined the available evidence to inform treatment selection based on the presence or absence of comorbidities in psoriatic arthritis (PsA).
Results Common comorbidities in PsA that may affect treatment selection include presence of baseline cardiovascular disease (CVD) or high risk for CVD, obesity and metabolic syndrome, liver disease, mood disorders, including depression in particular, chronic infections, malignancies, osteoporosis, and fibromyalgia and/or central sensitization.
Conclusion Comorbidities may influence both the effectiveness of a given therapy but also the potential for adverse events. It is important to assess for the presence of comorbidities prior to therapy selection.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Cristiano B. Campanholo, Ajesh B. Maharaj, Nadia Corp, Stacie Bell, Luisa Costa, Kurt de Vlam, Nicola J. Gullick, Majed Khraishi, Mitsumasa Kishimoto, Natalia Palmou-Fontana, Soumya Reddy, Raffaele Scarpa, Luis Vega, Gleison Vieira Duarte, Devy Zisman, Danielle A. van der Windt, Mehmet T. Duruoz, Alexis Ogdie
The Journal of Rheumatology Nov 2022, jrheum.220310; DOI: 10.3899/jrheum.220310
Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Cristiano B. Campanholo, Ajesh B. Maharaj, Nadia Corp, Stacie Bell, Luisa Costa, Kurt de Vlam, Nicola J. Gullick, Majed Khraishi, Mitsumasa Kishimoto, Natalia Palmou-Fontana, Soumya Reddy, Raffaele Scarpa, Luis Vega, Gleison Vieira Duarte, Devy Zisman, Danielle A. van der Windt, Mehmet T. Duruoz, Alexis Ogdie
The Journal of Rheumatology Nov 2022, jrheum.220310; DOI: 10.3899/jrheum.220310
